Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Much Will The Chronic Hepatitis B Market Be Worth By 2029?

The market size for chronic hepatitis b has been witnessing consistent growth over the past few years. It is projected to increase from $3.77 billion in 2024 to $3.93 billion in 2025, at a Compound Annual Growth Rate (CAGR) of 4.2%. The prior growth can be credited to advancements in antiviral therapy, escalating initiatives by the government and NGOs, bettered diagnostic methodologies, a climbing incidence of HIV, and a boost in awareness.

The market size for chronic hepatitis b is forecasted to experience consistent growth over the upcoming years, reaching $4.59 billion in 2029 with a 4.0% compound annual growth rate (CAGR). The upward trend during this forecast period is predicated on numerous factors such as the widening scope in emerging markets, progressive governance policies and financial backing, advancements in diagnostics and screenings, augmented healthcare spending, increasing strategic affiliations and partnerships, the expansion of the aging populace, and growth in public consciousness campaigns. Key patterns for the forecast period incorporate a transition towards curative therapies, the broadening in emerging markets, improved diagnostics and screening, alliances and cooperation, and a spotlight on personalized patient care.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

What External And Internal Drivers Are Influencing The Chronic Hepatitis B Market?

The chronic hepatitis B virus market is anticipated to grow due to the high incidence of chronic hepatitis B infection. Hepatitis B, a liver disease caused by the hepatitis B virus (HBV), can be prevented by vaccination. However, the increase in hepatitis B infection rates results from several factors, especially in low to middle-income countries, where poor vaccination coverage leads to heightened transmission rates due to a large unvaccinated population. Consequently, higher infection rates lead to greater demand for diagnostic tests and treatment alternatives. For example, a report by the US-based government agency, Centers for Disease Control and Prevention, in June 2024, suggested that increasing global hepatitis B vaccination coverage to 90% and expanding treatment access to 80% could prevent 26 million new infections and 9 million deaths linked to hepatitis B between 2022 and 2050. In 2022, there were 1.2 million fresh hepatitis B virus cases. Hence, the substantial occurrence of hepatitis B infection is likely to stimulate the expansion of the chronic hepatitis B virus market.

What Segmentation Insights Are Provided In The Chronic Hepatitis B Market Research?

The chronic hepatitis bmarket covered in this report is segmented –

1) By Drug Class: Antivirals; Immune Modulators

2) By Gender: Male; Female

3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers

Subsegments:

1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir); Interferons (Pegylated Interferon)

2) By Immune Modulators: Immune Checkpoint Inhibitors; Therapeutic Vaccines (HBV Vaccines Under Development)

Which Market Trends Are Expected To Define The Future Of The Chronic Hepatitis B Market?

The primary players in the chronic hepatitis B market are concentrating on technological advancements, notably the development of new antiviral treatments. These pioneering medications are designed to combat viral infections, particularly those that are resistant, by preventing replication and utilizing advanced delivery methods. They are currently undergoing clinical trials for safety and effectiveness, with bepirovirsen being a key focus for combatting chronic hepatitis B. In February 2024, GSK plc, a multinational pharmaceutical and biotechnology company based in the UK with a broad portfolio of healthcare products, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for bepirovirsen. This investigational antisense oligonucleotide (ASO) is targeting to treat chronic hepatitis B (CHB). The drug, bepirovirsen, aims to degrade the hepatitis B virus (HBV)’s RNA to potentially enable the immune system to reclaim control of the infection. The medication has shown promising outcomes in Phase IIb studies, namely B-Clear and B-Sure, where it successfully reduced hepatitis B surface antigen (HBsAg) levels and achieved prolonged viral suppression.

Who Are The Leading Companies Driving The Chronic Hepatitis B Market?

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Chronic Hepatitis B Market?

North America was the largest region in the chronic hepatitis B market in 2024. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp

Browse Through More Reports Similar to the Global Chronic Hepatitis B Market 2025, By The Business Research Company

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Lower Back Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model